Page last updated: 2024-11-02

pirenzepine and Obesity

pirenzepine has been researched along with Obesity in 29 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea."9.10Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003)
"It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment."9.10Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003)
"The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine."9.10Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002)
"First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)."9.10Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"Acute cholinergic muscarinic blockade with pirenzepine significantly reduces meal stimulated plasma insulin and plasma glucose concentrations in clinically hyperandrogenic women with polycystic ovary syndrome."9.07Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome. ( Ismail, IS; Miell, JP; Peters, JR; Premawardhana, LD; Riad-Fahmy, D; Scanlon, MF, 1994)
"A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy."7.70H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000)
"A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea."5.10Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003)
"It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment."5.10Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003)
"The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine."5.10Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002)
"First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)."5.10Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol."5.09Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999)
"Acute cholinergic muscarinic blockade with pirenzepine significantly reduces meal stimulated plasma insulin and plasma glucose concentrations in clinically hyperandrogenic women with polycystic ovary syndrome."5.07Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome. ( Ismail, IS; Miell, JP; Peters, JR; Premawardhana, LD; Riad-Fahmy, D; Scanlon, MF, 1994)
"The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment."3.72Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003)
"One of my patients is taking olanzapine for schizophrenia."3.71Maternal obesity and risk of neural tube defects. ( Koren, G, 2001)
"A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy."3.70H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. ( Bravi, D; Guarneri, L; Sacchetti, E, 2000)
"Peak plasma glucose in NIDDMs was reduced following pirenzepine (12."2.67Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics. ( Ara, J; Bevan, JS; Page, MD; Peters, JR; Scanlon, MF, 1991)
"Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other."1.31Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002)
"Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)."1.30Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999)
" We have evaluated the consequences of HFD on heart rate (HR) and blood pressure (BP) circadian cycles and methylscopolamine dose-response curves."1.30Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension. ( Berlan, M; Galitzky, J; Merial, C; Montastruc, JL; Pelat, M; Senard, JM; Verwaerde, P, 1999)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.45)18.7374
1990's9 (31.03)18.2507
2000's18 (62.07)29.6817
2010's1 (3.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, X1
Zhao, Y1
Shao, H1
Zheng, X1
Hermida, T1
Franco, K1
Hadi, F1
Douyon, K1
Atmaca, M2
Kuloglu, M2
Tezcan, E2
Ustundag, B2
Pae, CU1
Kim, JJ1
Lee, KU1
Lee, CU1
Bahk, WM1
Lee, SJ1
Lee, C1
Paik, IH1
Tavakoli, SA1
Arguisola, MS1
Littrell, KH1
Hilligoss, NM1
Kirshner, CD1
Petty, RG1
Johnson, CG1
de la Pierre, M1
Aricò, S1
Capussotti, L1
Dellepiane, M1
Marucci, M1
Gandini, G1
Imarisio, P1
Premawardhana, LD1
Ismail, IS1
Riad-Fahmy, D1
Miell, JP1
Peters, JR2
Scanlon, MF2
Maccario, M1
Procopio, M1
Grottoli, S1
Oleandri, SE1
Razzore, P1
Camanni, F1
Ghigo, E1
Aquila, R1
Emanuel, M1
Wirshing, DA1
Wirshing, WC1
Kysar, L1
Berisford, MA1
Goldstein, D1
Pashdag, J1
Mintz, J1
Marder, SR1
Ganguli, R1
Masand, PS1
Bryden, KE1
Kopala, LC2
Pelat, M1
Verwaerde, P1
Merial, C1
Galitzky, J1
Berlan, M1
Montastruc, JL1
Senard, JM1
Karagianis, J1
Sacchetti, E1
Guarneri, L1
Bravi, D1
Jones, B1
Basson, BR1
Walker, DJ1
Crawford, AM1
Kinon, BJ1
Allison, DB1
Casey, DE1
Umbricht, D1
Flury, H1
Bridler, R1
Koren, G1
Simpson, MM1
Goetz, RR1
Devlin, MJ1
Goetz, SA1
Walsh, BT1
Baptista, T1
Beaulieu, S1
McIntyre, RS1
Gothelf, D1
Falk, B1
Singer, P1
Kairi, M1
Phillip, M1
Zigel, L1
Poraz, I1
Frishman, S1
Constantini, N1
Zalsman, G1
Weizman, A2
Apter, A1
Poyurovsky, M1
Pashinian, A1
Gil-Ad, I1
Maayan, R1
Schneidman, M1
Fuchs, C1
Webster, D1
Devarajan, S1
Gallant, J1
Harris, A1
Bevan, JS1
Ara, J1
Page, MD1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]Phase 416 participants (Actual)Interventional2005-12-31Completed
A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366]261 participants (Actual)Interventional2004-05-31Completed
Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562]Phase 320 participants (Actual)Interventional2005-10-31Terminated
The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398]12 participants (Actual)Observational2013-04-29Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Body Mass Index (BMI)

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionkg/m^2 (Mean)
Aripiprazole-0.4
Placebo0.3

Change From Baseline in Fasting Total Cholesterol

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-3
Placebo9

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole0.4
Placebo0.6

Change From Baseline in Low-density Lipoprotein (LDL)

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-0.2
Placebo3.1

Change From Baseline in Triglycerides

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-51.7
Placebo47.6

Change From Baseline in Waist-hip Ratio (WHR)

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventioncm (Mean)
Aripiprazole0.0
Placebo0.0

Change From Baseline in Weight (Lbs)

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionlbs (Mean)
Aripiprazole-2.9
Placebo2.1

Reviews

2 reviews available for pirenzepine and Obesity

ArticleYear
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 2

    Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up

2001
Antipsychotic-induced weight gain: a review of the literature.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 7

    Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Female; Humans; Mal

2001

Trials

8 trials available for pirenzepine and Obesity

ArticleYear
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
    Human psychopharmacology, 2003, Volume: 18, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Histamine H2 Antagonists; Humans; Male; Nizati

2003
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.
    Human psychopharmacology, 2003, Volume: 18, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Histamine H2 Antagonists;

2003
The effects of an educational intervention on antipsychotic-induced weight gain.
    Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, 2003, Volume: 35, Issue:3

    Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Body Mass Index; Female; Health Kn

2003
Acute cholinergic blockade with low dose pirenzepine reduces the insulin and glucose responses to a mixed meal in obese women with the polycystic ovary syndrome.
    Clinical endocrinology, 1994, Volume: 40, Issue:5

    Topics: Adult; Androstenedione; Blood Glucose; Carrier Proteins; Dose-Response Relationship, Drug; Eating; F

1994
Novel antipsychotics: comparison of weight gain liabilities.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I

1999
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
    The American journal of psychiatry, 2002, Volume: 159, Issue:6

    Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta

2002
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    The American journal of psychiatry, 2002, Volume: 159, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co

2002
Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics.
    Clinical endocrinology, 1991, Volume: 35, Issue:1

    Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Respo

1991

Other Studies

19 other studies available for pirenzepine and Obesity

ArticleYear
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.
    Psychoneuroendocrinology, 2019, Volume: 108

    Topics: Animals; Benzodiazepines; Blood Glucose; Body Weight; Dyslipidemias; Energy Metabolism; Fatty Liver;

2019
Weight gain associated with atypical antipsychotics.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:11

    Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity

2002
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:5

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female

2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
    Southern medical journal, 2003, Volume: 96, Issue:7

    Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi

2003
[Description of a case of Zollinger-Ellison syndrome].
    Minerva medica, 1984, May-07, Volume: 75, Issue:19

    Topics: Benzodiazepinones; Body Weight; Cimetidine; Diarrhea; Female; Gastrectomy; Gastric Acid; Humans; Mid

1984
In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:12

    Topics: Adult; Arginine; Female; Glucose; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Mu

1995
Weight gain and antipsychotic medications.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid

1999
Weight gain associated with antipsychotic drugs.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 21

    Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations;

1999
Relative weight gain among antipsychotics.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid

1999
Body mass index increase of 58% associated with olanzapine.
    The American journal of psychiatry, 1999, Volume: 156, Issue:11

    Topics: Adolescent; Benzodiazepines; Body Mass Index; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizo

1999
Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 34, Issue:5

    Topics: Adenylyl Cyclases; Animals; Blood Pressure; Body Weight; Dogs; Dose-Response Relationship, Drug; Hea

1999
Olanzapine and weight gain.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:5

    Topics: Adult; Benzodiazepines; Female; Humans; Obesity; Olanzapine; Pirenzepine; Psychotic Disorders; Selec

2000
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.
    Biological psychiatry, 2000, Jul-15, Volume: 48, Issue:2

    Topics: Adult; Benzodiazepines; Brief Psychiatric Rating Scale; Histamine H2 Antagonists; Humans; Male; Niza

2000
Cognitive behavior therapy for weight gain.
    The American journal of psychiatry, 2001, Volume: 158, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Cognitive Behavioral Ther

2001
Maternal obesity and risk of neural tube defects.
    Canadian family physician Medecin de famille canadien, 2001, Volume: 47

    Topics: Antipsychotic Agents; Benzodiazepines; Female; Folic Acid; Humans; Infant, Newborn; Neural Tube Defe

2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:9

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu

2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic

2001
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
    The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 3

    Topics: Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Female; Fructose; Humans; La

2002
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
    Schizophrenia research, 2002, Jul-01, Volume: 56, Issue:1-2

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud

2002